Navigation Links
EVT in Medical News

Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness

Statistical Significance in Primary and Key Secondary Endpoints at Both Doses Data Confirm Robust Sleep Onset and Sleep Maintenance Effects Seen in the First Phase II Study in the Adult Population HAMBURG, Germany and OXFORD, England, October 16 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt...

Alzheimer’s disease trial With EVT 101 For Successfully Complete

Alzheimer’s disease is a dreaded disease for the elderly. In the direction of its treatment , the effort of Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") has successfully completed the single ascending dose component // of the Phase I clinical study with EVT 101, a subtype-specific...
EVT in Medical Technology

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

Single-Dose, Volunteer fMRI Study Completed and Reported Today Dosing in Four Week Higher Repeat Dose Study Completed HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/ -- Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the preliminary findings of ...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Both Co-Primary Endpoints, Wake After Sleep Onset and Total Sleep Time, and Key Secondary Endpoints, Including Latency to Persistent Sleep, Were Met at Both Doses HAMBURG, Germany and OXFORD, England, June 04, 2007 /PRNewswire-FirstCall/ -- Evotec AG announced today positive top-line results from ...

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...

... results from its first phase II clinical trial of evt 201 in patients with chronic primary insomnia. evt 201 is a partial positive allosteric modulator (pP...controlled cross-over study design of two doses of evt 201 (1.5mg and 2.5mg) in 67 patients was conducted...
EVT in Biological Technology

Evotec Starts Phase II in Smoking Cessation with EVT 302

HAMBURG, Germany and OXFORD, England, February 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B). This doubl...

Phase I Safety and Tolerability Study With EVT 302 Successfully Completed

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 ...

Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201

Very Robust Findings on the Key Problems Faced by Insomniacs, i.e. Sleep Onset and Sleep Maintenance Evotec to Host a Conference Call Today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) Directly From the Worldsleep07 Congress in Australia HAMBURG, Germany and OXFORD, England,...

Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia

HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at...

Evotec Announces Financial Results for 2007

... Positive data from two Phase II trials evaluating evt 201 strengthening confidence in evt 201's potential advantages over competitive insomnia therapies - Phase I safety data for evt 302 revealed good tolerance up to the highest d...

Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis

...logies acquired ("In-process Research and Development") in the amount of EUR 38.5 million, in particular to Evotec's clinical programs EVT 201 and the evt 100 series, which according to IFRS has to be capitalized and to be carried forward according to IAS 38. EUR 7.1 million was allocated to the customer...

Evotec Reports Third Quarter 2007 Results

... Phase II trials with lead insomnia drug candidate evt 201 - Sale of the Chemical Development Business t... two Phase II studies with insomnia drug candidate evt 201 - In adult insomniacs (first study), evt 201 showed highly statistically significant effect...

Evotec AG: R&D Update on 16 October 2007 Live on the Internet

...entral Nervous System. Evotec has three programmes in clinical development: evt 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor c...ceptor antagonist for the treatment of Alzheimer's disease and/or pain, and evt 302, a MAO-B inhibitor in development for smoking cessation. On 19 Septemb...

Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York

...entral Nervous System. Evotec has three programmes in clinical development: evt 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor c...ceptor antagonist for the treatment of Alzheimer's disease and/or pain, and evt 302, a MAO-B inhibitor in development for smoking cessation. http://www.e...
Other Tags
(Date:8/28/2015)... , ... August 28, 2015 ... ... Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on two ... demonstration approved for a December 2015 launch; and Idaho’s partnership to revamp ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... organization, is pleased to welcome TJS Insurance Group as its newest Partner Firm. ... clients guides them and keeps them focused on their goals. Within the past ...
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review ... millionaire dating sites . According to the listings, MillionaireMatch.com bags ... this category. , A spokesperson of Top5MillionaireDatingSites.com said, “This website has ...
(Date:8/28/2015)... Calgary, AB (PRWEB) , ... August 28, 2015 , ... ... disease. The Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines ... The Heart Fit Clinic has been in business since 2007 helping people prevent and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Plaintiffs Steering Committee ... 2545, Testosterone Replacement Therapy Products Liability Litigation, are in the midst of ongoing ... the PSC may receive for corporate employees involved in the production or marketing ...
Breaking Medicine News(10 mins):Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
Other Contents